{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:03:46Z","timestamp":1792598626367,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.braindev.2025.104424","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T03:04:22Z","timestamp":1755831862000},"page":"104424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Gene therapy for Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"47","author":[{"given":"Yuko","family":"Shimizu-Motohashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2025.104424_bb0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2025.104424_bb0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2025.104424_bb0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/acn3.51829","article-title":"Newborn screening for Duchenne muscular dystrophy: a two-year pilot study","volume":"10","author":"Tavakoli","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2025.104424_bb0020","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/mus.28255","article-title":"The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: a single-center study of 555 patients","volume":"70","author":"Zygmunt","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2025.104424_bb0025","first-page":"2471","article-title":"Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials","volume":"8","author":"Shimizu-Motohashi","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.braindev.2025.104424_bb0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2025.104424_bb0035","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2025.104424_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/hum.2019.173","article-title":"Transduction efficiency of adeno-associated virus serotypes after local injection in mouse and human skeletal muscle","volume":"31","author":"Muraine","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0050","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0065","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/hum.2016.141","article-title":"Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne muscular dystrophy, Becker muscular dystrophy, inclusion body myositis, or GNE myopathy","volume":"28","author":"Zygmunt","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0070","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/hum.2022.081","article-title":"Seroprevalence of adeno-associated virus neutralizing antibodies in males with Duchenne muscular dystrophy","volume":"34","author":"Verma","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0075","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2025.104424_bb0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14712598.2024.2371042","article-title":"Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures","volume":"24","author":"Mizoguchi","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0085","unstructured":"U.S. Food & Drug Administration. Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy [Internet]. 2015 August [cited 2025 May 18]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products."},{"key":"10.1016\/j.braindev.2025.104424_bb0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nmeth.2649","article-title":"Cas9 as a versatile tool for engineering biology","volume":"10","author":"Mali","year":"2013","journal-title":"Nat Methods"},{"key":"10.1016\/j.braindev.2025.104424_bb0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/hum.2023.053","article-title":"CRISPR-editing therapy for Duchenne muscular dystrophy","volume":"34","author":"Chemello","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0100","unstructured":"Sarepta Therapeutics. Sarepta therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat duchenne muscular dystrophy [Internet]. 2023 Jun 22 [cited 2025 May 18]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene."},{"key":"10.1016\/j.braindev.2025.104424_bb0105","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics announces expanded US FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above [Internet]. 2024 Jun 20 [cited 2025 May 18]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys."},{"key":"10.1016\/j.braindev.2025.104424_bb0110","unstructured":"U.S. Food & Drug Administration. Elevidys. [Internet]. 2025 June [cited 2025 July 26]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"key":"10.1016\/j.braindev.2025.104424_bb0115","unstructured":"Roche. Roche provides regulatory update on Elevidys\u2122 gene therapy for Duchenne muscular dystrophy in the EU.[Internet]. 2025 July [cited 2025 July 26]. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2025-07-25."},{"key":"10.1016\/j.braindev.2025.104424_bb0120","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1007\/s00415-024-12431-z","article-title":"Immune-mediated myositis following gene therapy for Duchenne muscular dystrophy: a case report","volume":"271","author":"Iannaccone","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2025.104424_bb0125","unstructured":"Chugai Pharmaceutical. Chugai Receives Regulatory Approval for \u201cELEVIDYS\u201d as a Gene Therapy Product for Duchenne Muscular Dystrophy in Japan [Internet]. 2025 May [cited 2025 July 26]. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20250513181500_1160.html."},{"key":"10.1016\/j.braindev.2025.104424_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2025.104424_bb0135","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2025.104424_bb0140","doi-asserted-by":"crossref","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.braindev.2025.104424_bb0145","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2025.104424_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical considerations for Delandistrogene Moxeparvovec gene therapy in patients with Duchenne muscular dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2025.104424_bb0155","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213604","article-title":"Delandistrogene Moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy: evidence in focus: report of the AAN guidelines subcommittee","volume":"104","author":"Oskoui","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2025.104424_bb0160","unstructured":"Sarepta Therapeutics. Strengthen safety in non-ambulatory individuals with Duchenne [Internet]. 2025 June [cited 2025 July 26]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-provides-safety-update-elevidys-and-initiates-steps."},{"key":"10.1016\/j.braindev.2025.104424_bb0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2024.38567.bfs","article-title":"Pfizer weighs next steps after DMD therapy linked to boy\u2019s death fails phase III trial","volume":"35","author":"Philippidis","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/hum.2022.29211.bfs","article-title":"Food and Drug Administration lifts clinical hold on Pfizer Duchenne muscular dystrophy gene therapy linked to patient death","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0175","unstructured":"Parent Project Muscular Dystrophy. Pfizer discontinues development of investigational mini-dystrophin gene therapy [Internet]. 2024 July 30 [cited 2025 May 18]. Available from: https:\/\/www.parentprojectmd.org\/pfizer-discontinues-development-of-investigational-mini-dystrophin-gene-therapy\/."},{"key":"10.1016\/j.braindev.2025.104424_bb0180","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104424_bb0185","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1089\/hum.2022.29228.bfs","article-title":"Brother of cure rare disease CEO dies in trial of Duchenne muscular dystrophy therapy","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101160","article-title":"Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications","volume":"31","author":"Roberts","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.braindev.2025.104424_bb0195","unstructured":"GenAssist Therapeutics. The first DMD clinical base editing drug! DMD treatment is entering the gene editing era! [Internet]. 2024 September 6 [cited 2025 May 18]. Available from: https:\/\/genassisttx.com\/blog\/2024\/09\/10\/genassistfirst-dmd-patient-dosed\/."},{"key":"10.1016\/j.braindev.2025.104424_bb0200","unstructured":"HuidaGene Therapeutics. HuidaGene therapeutics initiates M.U.S.C.L.E. clinical trial of HG302 for Duchenne muscular dystrophy and completes first patient dosed. [Internet]. 2024 December 12 [cited 2025 May 18]. Available from: https:\/\/www.huidagene.com\/new\/news\/72."},{"key":"10.1016\/j.braindev.2025.104424_bb0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.braindev.2025.104424_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101349","article-title":"Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patients","volume":"32","author":"Emami","year":"2024","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.braindev.2025.104424_bb0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.braindev.2025.104424_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101195","article-title":"Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74","volume":"32","author":"Potter","year":"2024","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.braindev.2025.104424_bb0225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.braindev.2025.104424_bb0230","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0235","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3233\/JND-230185","article-title":"Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for patients with Duchenne muscular dystrophy","volume":"11","author":"Zaidman","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.braindev.2025.104424_bb0240","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104424_bb0245","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1089\/hum.2024.013","article-title":"Long-term survival and myocardial function following Systemic delivery of Delandistrogene Moxeparvovec in DMD(MDX) rats","volume":"35","author":"Baine","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0250","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.ymthe.2024.07.026","article-title":"Full-length dystrophin gene therapy for Duchenne muscular dystrophy","volume":"32","author":"Duan","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104424_bb0255","article-title":"Delivery of genetic medicines for muscular dystrophies","volume":"6","author":"Chulanova","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.braindev.2025.104424_bb0260","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","article-title":"Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.braindev.2025.104424_bb0265","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:58:42Z","timestamp":1764403122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760425001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0387760425001068"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104424","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V. CC BY 4.0","name":"copyright","label":"Copyright"}],"article-number":"104424"}}